SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN is trending following a retail frenzy fueled by discussions around recent federal cannabis reclassification, seen as a significant catalyst for the sector. The community highlights WEEDCOIN as the primary beneficiary and a leading cultural play within the Solana ecosystem, positioning it as an on-chain alternative to traditional pharmaceutical models. Sentiment emphasizes its potential for substantial growth as the "Green Wave" gains momentum.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is actively debated as strong US economic data, including robust GDP and softening inflation, fuels optimism for a year-end rally. However, community sentiment is split, with many cautioning against "inorganic" holiday trading and potential global liquidity shifts, while others see DIA as an old economy barometer confirming broader market strength or weakness.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Token is actively trending as discussions focus on its real-world utility through Flexa's expanding merchant network, enabling crypto payments at major retailers like Chipotle and Nordstrom. This visibility fuels optimism among long-term holders for future adoption and significant price recovery, contrasting with skepticism from those wary of past volatility and downward price trends. The community remains divided, debating whether current momentum signals a sustained uptrend or another fleeting pump.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is gaining attention for its expanding anticoagulation pipeline, highlighted by recent acquisitions and significant progress on its lead candidate, tecarfarin, including manufacturing readiness and a collaboration with Abbott. This "quiet expansion" is sparking community interest, with many anticipating a breakout given its low float and regulatory designations. However, skepticism persists among some regarding the company's financial stability and potential dilution.

TotalEnergies SE is a global integrated energy company, which engages in the production of oil and biofuels, natural gas and green gases, renewables and electricity. It operates through the following business segments: Exploration & Production, Integrated LNG, Integrated Power, Refining & Chemicals, and Marketing & Services. The Exploration & Production segment encompasses oil and natural gas exploration and production activities. The Integrated LNG segment includes the integrated gas chain (including upstream and midstream LNG activities) as well as biogas, hydrogen and gas trading activities. The Integrated Power segment involves in the generation, storage, electricity trading and B2B-B2C distribution of gas and electricity. The Refining & Chemicals segment engages in the activities of refining, petrochemicals and specialty chemicals. This segment also includes the activities of oil supply, trading and marine shipping. The Marketing & Services segment includes the global activities of supply and marketing in the field of petroleum products. The company was founded on March 28, 1924 and is headquartered in Courbevoie, France.

TotalEnergies SE

Total Energies

TotalEnergies is trending as it expands its clean energy footprint with significant long-term deals, including powering Google's data centers, and actively pursues high-potential deepwater oil and gas exploration projects. The community is discussing its compelling dividend yield and strategic portfolio transformation, alongside its potential consideration for a New York listing to enhance valuation.

Parker-Hannifin Corp. engages in the manufacture of motion and control technologies and systems. It operates through the Diversified Industrial and Aerospace Systems segments. The Diversified Industrial segment sells products to both original equipment manufacturers and distributors who serve the replacement markets in manufacturing, packaging, processing, transportation, mobile construction, refrigeration and air conditioning, agricultural and military machinery, and equipment industries. The Aerospace Systems segment offers products primarily in the commercial and military aerospace markets to both OEMs and to end users for spares, maintenance, repair, and overhaul. The company was founded by Arthur L. Parker in 1918 and is headquartered in Cleveland, OH.

Parker-Hannifin Corp.

Parker-Hannifin ($PH) is trending following its strategic acquisition of Filtration Group for over $9 billion, a move anticipated to significantly expand its market leadership and boost future earnings. This major corporate development, combined with continued strong performance in its Aerospace Systems segment and its reputation as a "Dividend King," is fueling bullish analyst sentiment and investor discussion, despite some debates around its current valuation.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is a key focus following its Marathon Oil acquisition, which enhances its low-cost U.S. shale portfolio and is projected to deliver over $1 billion in annual synergies. The community is actively discussing COP's strong Q4 earnings beat, substantial shareholder return commitments, and strategic moves in LNG and Arctic exploration. Investors are weighing these developments against volatile oil prices and geopolitical events, highlighting the company's long-term resilience.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending as discussions center on its strategic positioning to capitalize on the multi-billion dollar Rural Health Transformation Program and its new TytoCare integration, aiming to expand virtual care in underserved areas. Community sentiment is sharply divided, with many anticipating a significant long-term rebound driven by healthcare reform and AI innovation, while others express deep frustration over past financial performance, leadership decisions, and persistent stock underperformance. The conversation reflects a strong divergence between high conviction in a future turnaround and calls for greater accountability from management.

SPDR Series Trust - State Street SPDR S&P Oil & Gas Exploration & Production ETF

SPDR Oil & Gas Exploration & Production ETF

The oil and gas exploration and production sector, represented by XOP, is fueling vigorous community debate, with many investors actively accumulating on perceived dips amidst discussions of a suppressed physical market and surging global demand from emerging economies and data centers. Despite ongoing geopolitical uncertainties and varied economic forecasts, there's a strong contrarian belief that the sector is building towards a significant long-term breakout into the late 2020s.

KKR & Co., Inc. operates as an investment firm. It offers alternative asset management as well as capital markets and insurance solutions. The firm's business segments include Asset Management and Insurance Business. The Asset Management segment engages in providing private equity, real assets, credit and liquid strategies, capital markets, and principal activities. The Insurance Business segment offers retirement, life insurance and reinsurance solutions to clients across individual and institutional markets. The company was founded by Henry Kravis, George R. Roberts, and Jerome Kholberg on May 1, 1976 and is headquartered in New York, NY.

KKR & Co. Inc

KKR & Co. Inc.

KKR is trending amid its aggressive strategic expansion into high-growth sectors like digital infrastructure, real estate, and healthcare, underpinned by strong capital raising and robust earnings. The firm's continuous deal-making and positive analyst sentiment are fueling investor discussions about its long-term trajectory in alternative asset management. Community chatter highlights KKR's positioning in AI-related infrastructure and its transition to a diversified, permanent capital model, drawing comparisons to leading financial institutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>As of December 26, 72 deaths have occurred, the company said on Monday.</li><li>SELLAS had said in August that it expects the 80 events to occur by year-end.&nbsp;</li><li>GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) traded 17% higher on Monday after the company said that it is approaching the final analysis of its late-stage trial in Acute Myeloid Leukemia. &nbsp;The company is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding. GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.<h2 class="st-heading-2">Final Analysis Nears</h2>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/default.aspx">said</a> on Monday. SELLAS had said in August that it expects the 80 events to occur by year-end.“We appreciate the continued dedication of the patients, families, and investigators participating in the pivotal Phase 3 REGAL trial where survival times, fortunately for patients and caregivers, appear longer than expected,” said SELLAS CEO Angelos Stergiou. “While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results.”<h2 class="st-heading-2">Interim Analysis</h2>In August, an Independent Data Monitoring Committee completed a pre-specified analysis of the trial and issued a positive recommendation to continue the trial without modification. No safety concerns were identified, and available efficacy data were consistent with expectations for continued trial conduct, the company then said.The study completed enrollment in April 2024, with a total of 126 patients randomized.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user called the current price “absurd” and opined the stock is worth double digits. “Right this second! Not tomorrow, not next week, not a year from now but immediately right this very second…DOUBLE DIGITS!,” they wrote.<stembedurl>https://www.stocktwits.com/Mr_Anderson007/message/640327741</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has more than tripled this year and risen by about 239% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharmaceuticals-to-meet-with-fda-in-2026-to-advance-experimental-lyme-disease-prevention-drug/cL75CPSRExm">Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

Equity

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.


<ul class="summary-bullets"><li>The company’s uranium production in Pinyon Plain Mine in Arizona and La Sal Complex in Utah beat the top end of previously reported guidance by about 11%.&nbsp;</li><li>Energy Fuels now expects to sell 360,000 pounds of finished triuranium octoxide in the fourth quarter of 2025, more than double from 160,000 pounds expected earlier.</li><li>The rare earths company also announced the completion of two long-term uranium sales contracts with U.S. nuclear power-generating companies.</li></ul>Energy Fuels Inc. (UUUU) shares climbed over 5% in Monday’s premarket trade after the company announced that its finished uranium production, mined uranium ore production, and uranium concentrate sales for FY 2025 exceeded previously announced guidance.The company’s Pinyon Plain Mine in Arizona and La Sal Complex in Utah mined over 1.6 million pounds of uranium in 2025, beating the top end of previously reported guidance by about 11%.Meanwhile, its White Mesa Mill in Utah produced over one million pounds of finished triuranium octoxide, a uranium compound, in 2025, also exceeding the top end of previously reported guidance.<h2 class="st-heading-2">Guidance Update</h2>Energy Fuels said it expects to sell 360,000 pounds of triuranium octoxide in the fourth-quarter (Q4) of 2025, more than double the 160,000 pounds expected earlier and a 50% increase from third-quarter (Q3) 2025 levels. Total gross uranium sales revenue for Q4 2025 is expected to be about $27 million.Energy Fuels also announced the completion of two long-term uranium sales contracts with U.S. nuclear power generating companies that are expected to contribute to the company’s deliveries between 2027 and 2032.Pursuant to these contracts, Energy Fuels expects sales of 780,000 to 880,000 pounds of triuranium octoxide in 2026, and anticipates additional sales in the spot and term markets. For 2027 to 2032, the company’s current portfolio of six long-term contracts is estimated to deliver 2.41 to 4.41 million pounds of triuranium octoxide.Energy Fuels also expects its cost of goods sold to start declining in the first-quarter (Q1) of 2026 as low-cost Pinyon Plain uranium is added to its inventory.<h2 class="st-heading-2">Rare Earth Focus</h2>Rare earth elements and critical metals have been in focus this year after China restricted supply following President Donald Trump’s export tariffs. China controls roughly 70% of global mining and nearly 90% of processing.As a result, there has been a renewed interest in companies positioned to supply critical materials outside China. Meanwhile, demand for rare earth minerals has been climbing in the U.S. and worldwide as crucial components in EV battery production.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/UUUU">UUUU shares</a> trended in the ‘bearish’ territory amid ‘low’ message levels over the past day.<figure class="image"><img style="aspect-ratio:1311/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_6_11_39_PM_png_56f1a40f94.webp" alt="On Stocktwits, retail sentiment around UUUU shares trended in the ‘bearish’ territory amid ‘low’ message levels over the past day." width="1311" height="154"></figure>Shares of UUUU are up over 186% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Energy Fuels' White Mesa mill in Utah. (Photo by: Jim West/UCG/Universal Images Group via Getty Images)

Why Is UUUU Stock Rising Today?

The company said that its finished uranium production, mined uranium ore production, and uranium concentrate sales for FY 2025 exceeded previously announced guidance. 

<ul class="summary-bullets"><li>SELLAS released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.&nbsp;</li><li>The company is also expected to release the final event-driven analysis for its galinpepimut-S (GPS) drug by the end of 2025.&nbsp;</li><li>Some retail investors anticipate a buyout or partnership in the near future based on its oncology drug pipeline.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock has been on investors’ radar over the past few weeks after the company released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.Shares of SLS are up over 78% in just a month and continue to rise as investors discuss the potential of the drug, forthcoming developments, and possibilities of an acquisition. The stock is up nearly 3% in Wednesday’s premarket trade at the time of writing.<h2 class="st-heading-2">Trial Updates</h2>The trial for the SLS009 drug involved combining it with azacitidine (AZA) and venetoclax (VEN) in patients diagnosed with relapsed or refractory acute myeloid leukemia with myelodysplastic-related changes (AML-MR).Patients in the study with limited prior treatment achieved a median overall survival of 8.9 months, outperforming the historical benchmark of approximately 2.5 months for this patient population. Results showed a 46% overall response rate across all participants and a 58% overall response rate in patients with one prior line of therapy.SELLAS said it plans to expand the study of SLS009 in combination with azacitidine and venetoclax among acute myeloid leukemia patients in the first quarter of 2026.Apart from these positive trial results, users are also anticipating more information about the company’s galinpepimut-S (GPS) drug. Earlier this year, SELLAS had said that it expects the final event-driven analysis for the drug to be completed and reported by the end of 2025.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around SLS stock has remained in the ‘bullish’ territory for over a week, and message volume stayed at ‘high’ levels. The volume of retail messages for the stock has jumped 680% in the past month.Apart from the drug discussions, users are also actively discussing the possibility of an acquisition.One user pointed to the potential for a buyout or partnership, citing recent examples such as Cidara Therapeutics, which was bought by Merck for $9.2 billion.<stembedurl>https://stocktwits.com/DSCallez/message/640053184</stembedurl>Another bullish user echoed the sentiment, saying they were looking past trial success and focusing instead on who the buyer could be.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/640055860</stembedurl>A third user said that even if the company did not provide updates on the GPS drug by the end of the year, it was still performing better than anyone expected, and a longer wait would mean a higher buyout price.<stembedurl>https://stocktwits.com/BobWayne/message/640054317</stembedurl><a href="https://stocktwits.com/symbol/SLS">Shares of SLS</a> are up over 197% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About?

SLS Stock- Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 


<ul class="summary-bullets"><li>Ramaco will repurchase shares over 24 months.</li><li>It intends to purchase shares with available funds.</li><li>Ramaco had signed an umbrella CRADA with U.S. Department of Energy to accelerate the discovery, mining, processing, and creation of rare earths</li></ul>Ramaco Resources shares were in the spotlight on Wednesday after its board authorized a share repurchase program of up to $100 million over 24 months, a sign of the firm's strong financial position, even after a sharp rally this year. The announcement sent its shares up more than 6% in premarket trading.The company intends to purchase shares under the repurchase program opportunistically, using available funds, ensuring sufficient liquidity to fund its capital development program.“With the closing of Ramaco's previously announced $600-plus million (before fees) in capital raises in the second half of 2025, we are well-positioned. We can now pursue opportunities to unlock value and maximize shareholder returns,” said Randall Atkins, Chairman and CEO of Ramaco.<h2 class="st-heading-2">Strong Demand For Rare Earths Bodes Well For Ramaco</h2>Beyond capital returns, investors are tracking Ramaco’s push into rare earth minerals.&nbsp; Demand for rare earth minerals has been surging in the United States and globally, as they have become crucial for the production of EV batteries, play a vital role in the global transition to clean energy, and enable advanced defense systems. According to a McKinsey report, global demand for rare earths is projected to triple by 2035. &nbsp;Ramaco earlier also signed an Umbrella Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Energy's ("DOE") National Energy Technology Laboratory ("NETL"), in a bid to accelerate the discovery, mining, processing, and creation of rare earths and critical minerals and materials at its Brook Mine in Sheridan, Wyoming.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around METC trended in “extremely bullish” territory amid “extremely high” message volume.<figure class="image"><img style="aspect-ratio:628/76;" src="https://news.stocktwits-cdn.com/METC_PNG_278c3de7e2.webp" alt="Retail sentiment around METC trended in “extremely bullish” territory amid “extremely high” message volume." width="628" height="76"></figure> Ramaco Resources' stock has surged more than 57% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Samples of rare-earth minerals from Baiyun'ebo or Bayan Obo mining district are on display at the Institute of Geology and Geophysics, Chinese Academy of Sciences (IGGCAS) on May 17, 2025, in Beijing, China. (Photo by VCG/VCG via Getty Images)

After A Sharp Rally In 2025, Ramaco Is Doubling Down With $100M Share Buyback

Ramaco’s CEO said that, with $600 million-plus (before fees) in capital raises in the second half of 2025, the firm is well-positioned to pursue opportunities to unlock value and maximize shareholder returns.

<ul class="summary-bullets"><li>The analyst cited BlackSky’s unique space-based imagery offering and a refreshed constellation by the end of 2026.&nbsp;</li><li>Jefferies expects these to contribute to the company’s topline at about 25% per year.</li><li>It also forecasts the space intelligence company’s sales doubling to $211 million by 2028.</li></ul>BlackSky Technology Inc. (<a href="https://stocktwits.com/symbol/BKSY">BKSY</a>) shares rose over 5% in Monday’s premarket trade after Jefferies initiated coverage on the space intelligence company.Jefferies awarded BlackSky stock a ‘Buy’ rating with a $23 price target, implying a potential 19.5% upside to its current price. The analyst highlighted its unique space-based imagery offering and a refreshed constellation by the end of 2026, expected to contribute to its topline at about 25% per year.Jefferies expects the company’s sales to double to $211 million by 2028, up from $108 million at present.<h2 class="st-heading-2">Gen-3 Capacity Expansion</h2>On Dec. 17, 2025, the company integrated its third Gen-3 satellite into commercial operations just three weeks after launch, marking an exponential increase in commissioning speed and in high-resolution 35-centimeter imagery, as well as AI-enabled analytics, for its global customer base.With this development, BlackSky customers have access to all three current Gen-3 satellites through the Spectra tasking and analytics platform. These can collect time-diverse, high-cadence day and nighttime imagery and high-off-nadir collections, with automated AI-enabled vessel, aircraft, and vehicle detection and identification analytics.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BKSY stock was in ‘bearish’ territory from ‘neutral’ a day ago, and message volume remained at ‘high’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1267/170;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_22_at_7_28_08_PM_png_b79888f454.webp" alt="On Stocktwits, retail sentiment around BKSY stock was in ‘bearish’ territory from ‘neutral’ a day ago, and message volume remained at ‘high’ levels at the time of writing." width="1267" height="170"></figure>One user said the company’s outlook looked better.<stembedurl>https://stocktwits.com/inflect1on/message/639839205</stembedurl>Shares of BlackSky Technology are up over 85% in the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Illustration of a satellite orbits Earth against a backdrop of space and a sunlit horizon (Representative image courtesy of Sergio Bonilla via Getty Images)

BlackSky Technology Is The Latest Space Stock To Grab Investor Attention — Jefferies Expects Sales To Double In A Few Years

Jefferies initiated BlackSky coverage with a ‘Buy’ rating and a $23 price target. 

<ul class="summary-bullets"><li>The announcement comes after factoring in contracted customer agreements and the company's year-end billings, buoyed by Rezolve’s partnerships with Microsoft and Google for its agentic platform.&nbsp;</li><li>The company also expected December revenues to exceed $17 million, making it the strongest month in its history.</li><li>Rezolve said it anticipated a GAAP net loss due to non-cash items and one-time costs, with positive adjusted EBITDA.</li></ul>Rezolve AI (RZLV) shares rallied nearly 27% on Tuesday morning after the company announced that its preliminary, unaudited year-end results show annual recurring revenue (ARR) for 2025 is expected to be double its original estimation.Rezolve now expects its ARR to exceed $200 million at the end of the year, which is double the company’s original objective of $100 million. This comes after factoring in the company's contracted customer agreements and year-end billings.The company also predicted that December would be its strongest month in history, with revenue expected to exceed $17 million. Although it anticipates a GAAP net loss due to non-cash items and one-time costs, it sees a positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA).<h2 class="st-heading-2">Partnerships And Blue-Chip Adoption</h2>Rezolve’s performance comes amid the rapid growth of its agentic commerce platform, which is used by over 650 enterprises globally across retail, hospitality, financial services, and other sectors.The company’s Rezolve Brain Suite, the enterprise AI platform powered by its proprietary LLM, brainpowa, has seen rapid uptake following its integrations with Microsoft and Google. In 2024, Rezolve entered into partnerships with both companies to bring Brain Suite to Microsoft’s Azure Marketplace and Google Cloud.Rezolve has also built a client roster that includes major global retailers such as Adidas, Burberry, Gucci, Tommy Hilfiger, PUMA, Target, Standard Chartered, and Commerzbank, among others.The company noted that it has processed over 51 billion API calls across Brain Commerce, hosted over 340 million unique mobile user sessions, and reached 57.7 million consumer devices through its SDK.<h2 class="st-heading-2">2026 Guidance</h2>Rezolve AI reaffirmed its expectation of $500 million or more in ARR at the end of 2026, in line with previously issued guidance. This would amount to an implied monthly recurring revenue of over $40 million by December 2026.“2025 has been a breakthrough year for Rezolve AI,” said Daniel M. Wagner, Chairman and CEO at Rezolve AI. “We now have extraordinary momentum heading into 2026 with strong revenue visibility, a growing base of contracted recurring revenue, and increasing confidence in our path forward.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around <a href="https://stocktwits.com/symbol/RZLV">RZLV</a> jumped to ‘neutral’ from ‘bearish’ levels over a week ago, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing. RZLV was also among the top trending stocks on the platform.<figure class="image"><img style="aspect-ratio:1294/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_16_at_8_32_29_PM_png_d7a0e7ffb5.webp" alt="Retail sentiment around RZLV jumped to ‘neutral’ from ‘bearish’ levels over a week ago, and message volume climbed to ‘normal’ from ‘low’ levels at the time of writing. " width="1294" height="146"></figure>One user believes RZLV is one of the best up-and-coming stocks.<stembedurl>https://stocktwits.com/DylanGFM/message/639296359</stembedurl>Shares of RZLV climbed more than 33% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Rezolve AI logo is seen displayed on a smartphone screen.

Rezolve AI Stock Shot Up Over 27% Today — How Did Microsoft, Google Help Double 2025 ARR Expectations?

The company now expects annual recurring revenue to exceed $200 million at the end of 2025, double its initial projection of $100 million. 

<ul class="summary-bullets"><li>The company highlighted an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial.&nbsp;</li><li>The company noted that the latest observation trended similarly to its Phase IIb trial results and hazard ratio.</li></ul>Greenwich LifeSciences, Inc.’s (GLSI) shares soared in premarket trading on Monday after the company announced positive results from its phase III clinical trial, FLAMINGO-01, evaluating an immunotherapy to prevent breast cancer recurrences.Greenwich highlighted about an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial.Shares of <a href="https://stocktwits.com/symbol/GLSI">GLSI</a> were up over 86% premarket at the time of writing.<h2 class="st-heading-2">Trial Details</h2>The company noted that the latest observation trended similarly to its Phase IIb trial results and hazard ratio, where the patients were treated, and breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.“Despite these being preliminary results that will mature and can change with time, seeing a reduction in expected recurrence rates that is trending towards a low HR of 0.2, which represents an 80% reduction in recurrence rate, is very encouraging and which is why along with the similarly promising safety and immune response data to date, we will seek to continue to treat non-HLA-A*02 patients in a placebo controlled manner in the study," said CEO Snehal Patel.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, GLSI was the second-most trending stock on Monday morning. The retail sentiment around GLSI continued to trend in the ‘extremely bullish’ territory compared to ‘bullish’ a month ago, while message volume has remained ‘extremely high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1279/145;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_5_07_16_PM_png_76f022ac17.webp" alt="Retail sentiment for GLSI at the time of writing was 'extremely bullish' and message volume was 'extremely high'." width="1279" height="145"></figure>One Stocktwits user said they would be watching the stock all day, indicating their bullish stance on the company.<stembedurl>https://stocktwits.com/Rolltide2020/message/639156747</stembedurl>Shares of GLSI are down over 16% over the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Mammogram imagery, regular mammogram on the left, and contrast enhanced mammogram on the right, on Thursday, Sept. 26, 2024 in Houston. (Brett Coomer/Houston Chronicle via Getty Images)

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 

Why Is GLSI Stock Rising Today? 

Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 


<ul class="summary-bullets"><li>BioCryst said the approval follows positive interim data from a trial that showed the drug is safe and well-tolerated.</li><li>The company is also seeking approval for the drug’s use in the targeted age group in Europe, Japan, Canada, and other countries.&nbsp;</li><li>Orladeyo in capsule form is already FDA-approved for treating the disorder in those over 12 years of age.&nbsp;</li></ul>BioCryst Pharmaceuticals, Inc. (BCRX) has received approval from the U.S. Food and Drug Administration (FDA) for Orladeyo, an oral pellet formulation for the treatment of a rare genetic disorder in children.The approval comes after positive interim data from the APeX-P trial, which showed it is safe and well-tolerated and effectively reduces monthly HAE attacks in young children, the company said in a statement.BioCryst has also filed an application for the drug’s use with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency. The company said it is exploring additional regulatory filings in other global territories, including Canada.Shares of <a href="https://stocktwits.com/symbol/BCRX">BCRX</a> jumped over 4% on Friday morning at the time of writing.<h2 class="st-heading-2">Breakthrough Treatment For Young Children</h2>Hereditary angioedema (HAE) is a rare genetic disorder that can cause sudden and severe swelling in the skin, face, limbs, gut, and air pathways with potential life-threatening consequences.Orladeyo will become the first approved oral drug for the treatment of hereditary angioedema (HAE) in children aged 2 to 12, the company said. All other treatments for HAE in the market for the targeted demographic are currently administered intravenously or through injections.A capsule formulation of Orladeyo for treating HAE in children over 12 years and older adults received FDA approval in December 2020.“As we mark five years since ORLADEYO first transformed care for those with HAE ages 12 and older, this approval extends the benefits of oral prophylactic therapy to a vulnerable and important part of the HAE community, children ages 2 to less than 12. We couldn’t be more excited to bring this treatment option to these kids and their caregivers,” said Jon Stonehouse, chief executive officer of BioCryst.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, BCRX was among the top five trending stocks on Friday morning. The retail sentiment around BCRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained ‘high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1267/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_12_at_6_36_49_PM_png_130ee4212d.webp" alt="BCRX sentiment and message volume on Stocktwits. " width="1267" height="136"></figure>One Stocktwits user commended the FDA news.<stembedurl>https://stocktwits.com/Kiwiarse/message/638975638</stembedurl>Shares of BCRX are down over 3% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

CANADA - 2025/10/14: In this photo illustration, the BioCryst Pharmaceuticals (Bio Cryst) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Are Retail Traders Going Gaga Over BioCryst Pharma Stock Today?

The FDA has approved the use of Orladeyo, an oral drug, for children aged 2–12 with a rare genetic disorder.

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Brelovitug is a late-stage experimental drug being studied for chronic hepatitis delta virus infection.&nbsp;</li><li>The transaction with Bluejay is expected to close in the first quarter of 2026.</li><li>Mirum said it had secured $200 million through a private placement to be used to fund clinical development and commercial activities following the proposed acquisition.</li></ul>Shares of Mirum Pharmaceuticals, Inc. (MIRM) fell as much as 5% on Monday morning after the company announced that it has agreed to buy privately held Bluejay Therapeutics in a deal worth up to $820 million.The move is aimed at advancing the company in rare disease by adding Bluejay’s Brelovitug to its portfolio. Brelovitug is a late-stage experimental drug being studied for chronic hepatitis delta virus (HDV) infection, a most severe form of viral hepatitis in which nearly half of those affected progress to liver-related death within 10 years of diagnosis.<h2 class="st-heading-2">Deal Terms</h2>Under the deal, Mirum has <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251208788160/en/Mirum-Pharmaceuticals-Enters-into-Definitive-Agreement-to-Acquire-Bluejay-Therapeutics-Expanding-Global-Leadership-in-Rare-Disease">agreed</a> to acquire all outstanding shares of Bluejay for $250 million in cash and $370 million in Mirum common stock, in addition to potential sales-based milestone payments of up to $200 million in cash.The transaction with Bluejay is expected to close in the first quarter of 2026, subject to regulatory approval and other customary closing conditions, the company added.<h2 class="st-heading-2">About the Liver Drug&nbsp;</h2>Brelovitug is currently in late stage trials for HDV. In mid-stage trials, Brelovitug demonstrated strong antiviral activity in HDV and improvements in liver enzyme levels and a favorable safety profile.Mirum said on Monday that it expects top-line data from the late-stage trial in the second half of 2026, with application to the FDA for potential approval slated for 2027.Mirum also said that it will evaluate strategic options for Bluejay’s additional investigational programs after closing of the deal.<h2 class="st-heading-2">Placement Announcement</h2>Mirum on Monday also said that it has entered into a definitive agreement with a syndicate of existing and new healthcare investors, for the sale of Mirum common stock and pre-funded warrants, in a private placement.The private placement is expected to result in gross proceeds of $200 million which will be used to fund clinical development and commercial activities following the proposed acquisition, the company said.<h2 class="st-heading-2">Expert Take</h2>Cantor Fitzgerald subsequently raised the price target on Mirum to $130 from $95, while keeping an ‘Overweight’ rating on the shares. The new price target represents a potential upside of about 90% from the stock’s closing price on Friday.Cantor opined that Mirum’s proposed acquisition of Bluejay under the agreed-upon terms is a “steal.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MIRM">MIRM</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:586/57;" src="data:image/png;base64,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" alt="MIRM’s Sentiment Meter and Message Volume as of 11:13 a.m. ET on Dec. 08, 2025 | Source: Stocktwits" width="586" height="57"><figcaption>MIRM’s Sentiment Meter and Message Volume as of 11:13 a.m. ET on Dec. 08, 2025 | Source: Stocktwits</figcaption></figure>MIRM stock has gained 64% this year and by about 57% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/apple-chip-chief-reportedly-dismisses-concerns-about-exit/cLIYHDjREmk">Apple Chip Chief Reportedly Dismisses Concerns About Exit: ‘I Love My Job’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal'

The move is aimed at advancing the company in rare disease by adding Bluejay’s Brelovitug to its portfolio.

Current Price	$235.99
Prev Close	$237.88
Open	$237.87
Dividend Yield	N/A
50-Day Moving Average	$237.37
Beta	N/A
Avg. Volume	15,116.84
PE Ratio	N/A

52-Week High	$248.26
52-Week Low	$160.03
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

VTWG
Vanguard Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VTWG News

VTWGVanguard Russell 2000 Growth ETF